The VJSessions - VJNeurology

The VJSessions bring together leading international experts for in-depth discussions on advances and debated topics across neurological diseases, including stroke, multiple sclerosis, movement disorders, and more.

Stroke Sessions

Life after stroke: novel secondary prevention strategies being explored

Approaches to enhancing reperfusion therapies for AIS: AI, lightweight imaging devices, & more

World Stroke Organization launches Rehabilitation Certification Program

Life after Stroke: Practical strategies for secondary prevention and rehabilitation

Life after stroke: First steps in secondary stroke prevention

Should incidentally discovered covert brain infarcts be treated with aspirin and statins?

Interim results from the PHOTONIC study: prehospital video triage for suspected stroke

Vocational rehabilitation for stroke: insights from a speech and language and occupational therapist

Surf therapy for stroke in the chronic phase of rehabilitation: insights from a surf clinic

Blood pressure targets in ICH: should we go low?

Wrap-up of ISC 2025 with the Chair and Vice Chair

Major unmet needs in the treatment of stroke

Trials investigating medium and distal vessel occlusions and other meeting highlights

Endovascular therapy in medium vessel occlusion stroke: findings from the DISTAL trial

ENRICH trial: early surgical intervention in intracerebral hemorrhage

ESO-ESMINT expedited recommendation on IVT before MT in acute ischemic stroke

ESO guidelines on MSUs for prehospital stroke management

Multiple Sclerosis Sessions

A discussion at EAN 2026 on the impact of climate change on neurological diseases

Distinguishing true relapses from pseudo-relapses in MS: the impact on clinical trial readouts

AssistMS: testing the value of an AI tool for MRI scan interpretation in clinical practice

AttackMS and ChariotMS: optimizing care from diagnosis to advanced disease

Challenges in MS care: feedback gaps and cost-saving missteps

The next steps for tolebrutinib in MS

Baseline characteristics in the HERCULES trial: tolebrutinib in non-relapsing SPMS

Navigating the treatment landscape in MS: the potential of BTK inhibitors

The potential role of BTK inhibitors in addressing MS treatment gaps

Positive Phase II data of novel anti-CD40L antibody frexalimab in MS

Exploring new treatment avenues in MS and beyond

Movement Disorders Sessions

A discussion at EAN 2026 on the impact of climate change on neurological diseases

Improving CNS delivery and distribution of Huntington's disease therapies

Update on huntingtin-lowering strategies under investigation for Huntington’s disease

Headache Sessions

Nutritional approaches for migraine management

General Neurology Sessions

Climate change in neurology